925 related articles for article (PubMed ID: 29207323)
1. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics.
Overchuk M; Zheng G
Biomaterials; 2018 Feb; 156():217-237. PubMed ID: 29207323
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
3. Overcoming tumor microenvironment obstacles: Current approaches for boosting nanodrug delivery.
Wang X; Zhang H; Chen X; Wu C; Ding K; Sun G; Luo Y; Xiang D
Acta Biomater; 2023 Aug; 166():42-68. PubMed ID: 37257574
[TBL] [Abstract][Full Text] [Related]
4. Physical oncology: New targets for nanomedicine.
Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
[TBL] [Abstract][Full Text] [Related]
5. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles.
Niu Y; Zhu J; Li Y; Shi H; Gong Y; Li R; Huo Q; Ma T; Liu Y
J Control Release; 2018 May; 277():35-47. PubMed ID: 29545106
[TBL] [Abstract][Full Text] [Related]
6. Evaluating Nanomedicines: Obstacles and Advancements.
Swierczewska M; Crist RM; McNeil SE
Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
[TBL] [Abstract][Full Text] [Related]
7. Strategies to improve tumor penetration of nanomedicines through nanoparticle design.
Zhang YR; Lin R; Li HJ; He WL; Du JZ; Wang J
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1519. PubMed ID: 29659166
[TBL] [Abstract][Full Text] [Related]
8. Modulating the tumor microenvironment with new therapeutic nanoparticles: A promising paradigm for tumor treatment.
Zhang Y; Ho SH; Li B; Nie G; Li S
Med Res Rev; 2020 May; 40(3):1084-1102. PubMed ID: 31709590
[TBL] [Abstract][Full Text] [Related]
9. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.
Swetha KL; Roy A
Drug Deliv Transl Res; 2018 Oct; 8(5):1508-1526. PubMed ID: 30128797
[TBL] [Abstract][Full Text] [Related]
10. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
11. Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy.
Zhang B; Shi W; Jiang T; Wang L; Mei H; Lu H; Hu Y; Pang Z
Oncotarget; 2016 Sep; 7(38):62607-62618. PubMed ID: 27566585
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicines for cancer therapy: current status, challenges and future prospects.
Bor G; Mat Azmi ID; Yaghmur A
Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
[TBL] [Abstract][Full Text] [Related]
13. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicines Targeting the Tumor Microenvironment.
Tong R; Langer R
Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
[TBL] [Abstract][Full Text] [Related]
15. Advances in targeting strategies for nanoparticles in cancer imaging and therapy.
Yhee JY; Lee S; Kim K
Nanoscale; 2014 Nov; 6(22):13383-90. PubMed ID: 25273283
[TBL] [Abstract][Full Text] [Related]
16. Designing Stimuli-Responsive Upconversion Nanoparticles that Exploit the Tumor Microenvironment.
Ovais M; Mukherjee S; Pramanik A; Das D; Mukherjee A; Raza A; Chen C
Adv Mater; 2020 Jun; 32(22):e2000055. PubMed ID: 32227413
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring.
Namiki Y; Fuchigami T; Tada N; Kawamura R; Matsunuma S; Kitamoto Y; Nakagawa M
Acc Chem Res; 2011 Oct; 44(10):1080-93. PubMed ID: 21786832
[TBL] [Abstract][Full Text] [Related]
18. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
Bharali DJ; Mousa SA
Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
[TBL] [Abstract][Full Text] [Related]
19. pH-sensitive nano-systems for drug delivery in cancer therapy.
Liu J; Huang Y; Kumar A; Tan A; Jin S; Mozhi A; Liang XJ
Biotechnol Adv; 2014; 32(4):693-710. PubMed ID: 24309541
[TBL] [Abstract][Full Text] [Related]
20. Effects of tumor microenvironments on targeted delivery of glycol chitosan nanoparticles.
Yhee JY; Jeon S; Yoon HY; Shim MK; Ko H; Min J; Na JH; Chang H; Han H; Kim JH; Suh M; Lee H; Park JH; Kim K; Kwon IC
J Control Release; 2017 Dec; 267():223-231. PubMed ID: 28917532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
